Logo image of HBC.OL

HOFSETH BIOCARE ASA (HBC.OL) Stock Fundamental Analysis

OSL:HBC - Euronext Oslo - NO0010598683 - Common Stock - Currency: NOK

1.88  +0.08 (+4.44%)

Fundamental Rating

1

Overall HBC gets a fundamental rating of 1 out of 10. We evaluated HBC against 72 industry peers in the Biotechnology industry. HBC has a bad profitability rating. Also its financial health evaluation is rather negative. HBC has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year HBC has reported negative net income.
HBC had a negative operating cash flow in the past year.
HBC had negative earnings in each of the past 5 years.
HBC had negative operating cash flow in 4 of the past 5 years.
HBC.OL Yearly Net Income VS EBIT VS OCF VS FCFHBC.OL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50M -100M

1.2 Ratios

HBC's Return On Assets of -36.91% is in line compared to the rest of the industry. HBC outperforms 45.33% of its industry peers.
With a Return On Equity value of -208.67%, HBC is not doing good in the industry: 62.67% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -36.91%
ROE -208.67%
ROIC N/A
ROA(3y)-32.56%
ROA(5y)-30.06%
ROE(3y)-185.37%
ROE(5y)-136.87%
ROIC(3y)N/A
ROIC(5y)N/A
HBC.OL Yearly ROA, ROE, ROICHBC.OL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300

1.3 Margins

HBC has a Gross Margin (34.13%) which is comparable to the rest of the industry.
In the last couple of years the Gross Margin of HBC has grown nicely.
HBC does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 34.13%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y128.49%
GM growth 5Y94.79%
HBC.OL Yearly Profit, Operating, Gross MarginsHBC.OL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600

More info and screens

0

2. Health

2.1 Basic Checks

HBC does not have a ROIC to compare to the WACC, probably because it is not profitable.
HBC has more shares outstanding than it did 1 year ago.
HBC has more shares outstanding than it did 5 years ago.
The debt/assets ratio for HBC is higher compared to a year ago.
HBC.OL Yearly Shares OutstandingHBC.OL Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M
HBC.OL Yearly Total Debt VS Total AssetsHBC.OL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

Based on the Altman-Z score of 1.28, we must say that HBC is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of 1.28, HBC perfoms like the industry average, outperforming 56.00% of the companies in the same industry.
HBC has a Debt/Equity ratio of 1.86. This is a high value indicating a heavy dependency on external financing.
HBC has a Debt to Equity ratio of 1.86. This is in the lower half of the industry: HBC underperforms 65.33% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.86
Debt/FCF N/A
Altman-Z 1.28
ROIC/WACCN/A
WACC8.51%
HBC.OL Yearly LT Debt VS Equity VS FCFHBC.OL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

HBC has a Current Ratio of 0.67. This is a bad value and indicates that HBC is not financially healthy enough and could expect problems in meeting its short term obligations.
HBC's Current ratio of 0.67 is on the low side compared to the rest of the industry. HBC is outperformed by 78.67% of its industry peers.
HBC has a Quick Ratio of 0.67. This is a bad value and indicates that HBC is not financially healthy enough and could expect problems in meeting its short term obligations.
HBC has a worse Quick ratio (0.33) than 85.33% of its industry peers.
Industry RankSector Rank
Current Ratio 0.67
Quick Ratio 0.33
HBC.OL Yearly Current Assets VS Current LiabilitesHBC.OL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

3

3. Growth

3.1 Past

HBC shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -8.42%.
The Revenue has grown by 17.81% in the past year. This is quite good.
The Revenue has been growing by 30.59% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-8.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%18.95%
Revenue 1Y (TTM)17.81%
Revenue growth 3Y43.22%
Revenue growth 5Y30.59%
Sales Q2Q%37%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
HBC.OL Yearly Revenue VS EstimatesHBC.OL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M
HBC.OL Yearly EPS VS EstimatesHBC.OL Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 0 -0.2 -0.4 -0.6 -0.8

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for HBC. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
HBC.OL Price Earnings VS Forward Price EarningsHBC.OL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
HBC.OL Per share dataHBC.OL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 0.6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

HBC does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

HOFSETH BIOCARE ASA

OSL:HBC (6/20/2025, 7:00:00 PM)

1.88

+0.08 (+4.44%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners37.62%
Inst Owner ChangeN/A
Ins Owners0.02%
Ins Owner ChangeN/A
Market Cap742.75M
AnalystsN/A
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.89
P/FCF N/A
P/OCF N/A
P/B 12.37
P/tB 42.17
EV/EBITDA N/A
EPS(TTM)-0.31
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.04
FCFYN/A
OCF(TTM)-0.02
OCFYN/A
SpS0.65
BVpS0.15
TBVpS0.04
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -36.91%
ROE -208.67%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 34.13%
FCFM N/A
ROA(3y)-32.56%
ROA(5y)-30.06%
ROE(3y)-185.37%
ROE(5y)-136.87%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y128.49%
GM growth 5Y94.79%
F-Score4
Asset Turnover0.76
Health
Industry RankSector Rank
Debt/Equity 1.86
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 10.24%
Cap/Sales 1.58%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.67
Quick Ratio 0.33
Altman-Z 1.28
F-Score4
WACC8.51%
ROIC/WACCN/A
Cap/Depr(3y)35.77%
Cap/Depr(5y)87.88%
Cap/Sales(3y)7.85%
Cap/Sales(5y)29.06%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-8.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%18.95%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)17.81%
Revenue growth 3Y43.22%
Revenue growth 5Y30.59%
Sales Q2Q%37%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-10.41%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-22.57%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-454.18%
OCF growth 3YN/A
OCF growth 5YN/A